Ronald Berenson, MD, Co-founder, is the President and CEO of Aequus BioPharma. He served as President and CEO of HemaQuest Pharmaceuticals during the company’s first three years, successfully ushering the company’s programs into early clinical development of its lead compounds. He is currently serving as an Entrepreneur in Residence at the University of Washington. Prior to HemaQuest, he was founder, director, President and CEO of Xcyte Therapies, and founder, director, Executive VP, Chief Medical Officer and Chief Scientific Officer for CellPro. He obtained his oncology training at Stanford University Medical Center, MD from Yale Medical School and BS from Stanford University.
Douglas Faller, MD, PhD, Co-founder, is the Karin Grunebaum Professor of Cancer Research, Director of the Boston University Cancer Center, Vice-Chairman of Hematology Research In the Department of Medicine, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine at Boston University School of Medicine. He received his MD from Harvard Medical School and PhD from the Massachusetts Institute of Technology, with post-graduate residency at the University of California San Francisco and subspecialty training in Hematology and Oncology at Brigham and Women's Hospital, the Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School.
Thalia Papayannopoulou, MD, Co-founder, is Professor of Medicine in the Division of Hematology at the University of Washington, the recipient of the William Dameshek Prize of the American Society of Hematology(1990), a former member of the National Advisory Council at the National Heart, Lung, and Blood Institute(1990-1993), a member of Hematopoiesis Study Section(NIH,1999-2002 and 2011-present). She is currently an associate editor for PlosOne(2011-present). She received her MD degree from the University of Athens and post-graduate training in the Departments of Pathology and Hematology at the University of Washington.
Susan Perrine MD, Co-founder, served as Chief Scientific Officer and VP, Clinical Affairs at HemaQuest Pharmaceuticals during the company’s first three years, and is a co-principal inventor of the HemaQuest short chain fatty acid (SCFA) technology platform. Dr. Perrine was President and Chief Scientific Officer of Gene Regulation Laboratories, the predecessor company of HemaQuest, and is currently President and Chief Medical Officer of Aricent Pharmaceuticals. Dr. Perrine is Professor of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics at Boston University School of Medicine (BU). She is also Director of the Hemoglobinopathy Thalassemia Research Unit at the BU Cancer Research Center. She received her MD from Tufts, a Master's Degree from the Harvard School of Public Health, and completed her residency and sub-specialty training at Tufts Medical Center, Boston Children's Hospital, the Dana-Farber Cancer Institute, and Harvard Medical School.
George Stamatoyannopoulos, MD, DSc, Co-founder, is Professor of Medicine, Pathology and Genome Sciences and Director of the Markey Molecular Medicine Center at the University of Washington in Seattle. He has been the recipient of the William Dameshek Prize and Stratton Medal of the American Society of Hematology, the Metcalf Prize of the International Society of Experimental Hematology, the Levine Prize of the American Society of Clinical Pathology, and has served as President of the American Society of Hematology and the founding President of the American Society of Gene Therapy. He has founded two other biotechnology companies, Targeted Genetics and Regulome. He received his MD, Doctor of Science degree and post-graduate training from the University of Athens and the Royal Hellenic Research Foundation.
Robert Williams, PhD, Co-founder, is an organic and medicinal chemist, who synthesizes novel small-molecules for therapeutic application in hematology and oncology. He is Distinguished Professor of Chemistry at Colorado State University and Co-director of the Experimental Therapeutics section of the Colorado State University Cancer Center. Professor Williams has a PhD in Organic Chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow at Harvard University.